Occult hepatitis C virus infection: What does it mean?

Liver International

Volumn 30, Issue 4, 2010, Pages 502-511

  Pham, Tram N Q ^a   Coffin, Carla S ^b   Michalak, Tomasz I ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Consequences of OCI; HCV genome detection; Hepatitis C virus; Immune system; Low level HCV infection; Occult HCV persistence

Indexed keywords

CYTOKINE; LIVER ENZYME;

ANTIVIRAL THERAPY; DISEASE COURSE; FOLLOW UP; HEPATITIS C VIRUS; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOCOMPETENT CELL; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER HISTOLOGY; NONHUMAN; NUCLEIC ACID AMPLIFICATION; NUCLEIC ACID HYBRIDIZATION; OCCULT HEPATITIS C VIRUS INFECTION; PROTEIN EXPRESSION; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA REPLICATION; SENSITIVITY ANALYSIS; VIRUS CARCINOGENESIS; VIRUS DETECTION; VIRUS GENOME; VIRUS INFECTION; VIRUS REPLICATION;

BIOPSY; CARCINOMA, HEPATOCELLULAR; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; GENOME, VIRAL; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RNA, VIRAL; SEVERITY OF ILLNESS INDEX;

EID: 77950625207     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02193.x     Document Type: Review

References (87)

1. Alberti A, Chemello L, Benvegnu L. Natural history of hepatitis C. J Hepatol 1999, 31:17-24.
2. Fried MW, Shiffman ML, Reddy KR. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-82.
3. Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: Management of Hepatitis C: 2002. Hepatology 2002, 36:S1-2.
4. Varghese R, Al Khaldi J, Asker H. Treatment of chronic hepatitis C genotype 4 with peginterferon alpha-2a plus ribavirin. Hepatogastroenterology 2009, 56:218-22.
5. Zignego AL, Ferri C, Monti M. Hepatitis C virus as a lymphotropic agent: evidence and pathogenetic implications. Clin Exp Rheumatol 1995, 13:S33-7.
6. Roque-Alfonso AM, Ducoulombier D, Di Liberto G. Compartmentalization of hepatitis C virus genotypes between plasma and peripheral blood mononuclear cells. J Virol 2005, 79:6349-57.
7. Pal S, Sulivan DG, Kim S. Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism. Gastroeneterology 2006, 130:1107-16.
8. Zignego AL, Giannini C, Monti M, Gragnani L. Hepatitis C virus lymphotropism: lessons from a decade of studies. Dig Liver Dis 2007, 39:S38-45.
9. Blackard JT, Kemmer N, Sherman KE. Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology 2006, 44:15-22.
10. Pham TNQ, Michalak TI. Occult persistence and lymphotropism of hepatitis C virus infection. World J Gastroenterol 2008, 14:2789-93.
11. Pham TNQ, Mercer SE, Michalak TI. Chronic hepatitis C and persistent occult hepatitis C virus infection are characterized by distinct immune cell cytokine expression profiles. J Viral Hepat 2009, 16:547-56.
12. Pham TNQ, King D, MacParland SA. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology 2008, 134:812-22.
13. Ducoulombier D, Roque-Afonso AM, Di Liberto G. Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes. Hepatology 2004, 39:817-25.
14. MacParland SA, Pham TN, Gujar SA, Michalak TI. De novo infection and propagation of wild-type hepatitis C virus in human T lymphocytes in vitro. J Gen Virol 2006, 87:3577-86.
15. Kondo Y, Sung VM, Machida K, Liu M, Lai MM. Hepatitis C virus infects T cells and affects interferon-gamma signaling in T cell lines. Virology 2007, 361:161-73.
16. Di Liberto G, Roque-Afonso AM, Kara R. Clinical and therapeutic implications of hepatitis C virus compartmentalization. Gastroenterology 2006, 131:76-84.
17. Navas S, Martin J, Quiroga JA. Genetic diversity and tissue compartmentalization of the hepatitis C virus genome in blood mononuclear cells, liver, and serum from chronic hepatitis C patients. J Virol 1998, 72:1640-6.
18. Roque-Afonso AM, Ducoulombier D, Di Liberto G. Compartmentalization of hepatitis C virus genotypes between plasma and peripheral blood mononuclear cells. J Virol 2005, 79:6349-57.
19. Forton DM, Karayiannis P, Mahmud N. Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. J Virol 2004, 78:5170-83.
20. Laporte J, Bain C, Maurel P. Differential distribution and internal translation efficiency of hepatitis C virus quasispecies present in dendritic and liver cells. Blood 2003, 101:52-7.
21. Zignego AL, Ferri C, Giannini C. Hepatitis C virus infection in mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma: evidence for a pathogenetic role. Arch Virol 1997, 142:545-55.
22. Ferri C, Monti M, LaCivita L. Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood 1993, 82:3701-4.
23. Mizorogi F, Hiramoto J, Nozato A. Hepatitis C virus infection in patients with B cell non-Hodgkin's lymphoma. Intern Med 2000, 39:112-7.
24. Martyak LA, Yeganeh M, Saab S. Hepatitis C and lymphoproliferative disorders: from mixed cryoglobulinemia to non-Hodgkin's lymphoma. Clin Gastroenterol Hepatol 2009, 7:900-5.
25. Pham TNQ, MacParland SA, Mulrooney PM. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004, 78:5867-74.
26. Radkowski M, Gallegos-Orozco JF, Jablonska J. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005, 41:106-14.
27. Castillo I, Rodriguez-Inigo E, Lopez-Alcorocho JM. Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis 2006, 43:1277-83.
28. Ciancio A, Smedile A, Giordanino C. Long-term follow-up of previous hepatitis C virus positive nonresponders to interferon monotherapy successfully retreated with combination therapy: are they really cured? Am J Gastroenterol 2006, 101:1811-6.
29. Pham TNQ, Mulrooney-Cousins PM, Mercer SE. Antagonistic expression of hepatitis C virus and alpha interferon in lymphoid cells during persistent occult infection. J Viral Hepat 2007, 14:537-48.
30. Castillo I, Pardo M, Bartolome J. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 2004, 189:7-14.
31. Gallegos-Orozco JF, Rakela J. Persistence of hepatitis C virus in peripheral blood mononuclear cells of sustained viral responders to pegylated interferon and ribavirin therapy. Dig Dis Sci 2008, 53:2564-8.
32. Hoare M, Gelson WT, Rushbrook SM. Histological changes in HCV antibody-positive, HCV RNA-negative subjects suggest persistent virus infection. Hepatology 2008, 48:1737-45.
33. Quiroga JA, Llorente S, Castillo I. Virus-specific T-cell responses associated with hepatitis C virus (HCV) persistence in the liver after apparent recovery from HCV infection. J Med Virol 2006, 78:1190-7.
34. Bernardin F, Tobler L, Walsh I. Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia. Hepatology 2008, 47:1446-52.
35. Halfon P, Bourliere M, Ouzan D. Occult hepatitis C virus infection revisited with ultrasensitive real-time PCR assay. J Clin Microbiol 2008, 46:2106-8.
36. Marcellin P, Boyer N, Gervais A. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997, 127:875-81.
37. Naga S, Raghuraman SHT, Liang JRB. Minute levels of HCV RNA persist for an extended period of time after clinical recovery from hepatitis C but are ultimately cleared 15th International Symposium on Hepatitis C Virus and Related Viruses 2008: 66
38. Maylin S, Martinot-Peignoux M, Moucari R. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008, 135:821-9.
39. George SL, Bacon BR, Brunt EM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009, 49:729-38.
40. Carreno V, Bartolome J, Castillo I, Quiroga JA. Does occult hepatitis C virus infection exist? J Clin Microbiol 2008, 46:3550-2.
41. Pham TNQ, Michalak TI. Factors influencing detection of low levels of hepatitis C virus (HCV) genome and its replication. J Hepatol 2009, 50:S129.
42. Pham TNQ, Michalak TI. Hepatitis C virus in peripheral blood mononuclear cells of individuals with isolated anti-hepatitis C virus antibody reactivity. Hepatology 2008, 48:350-1.
43. Germer JJ, Zein NN. Advances in the molecular diagnosis of hepatitis C and their clinical implications. Mayo Clin Proc 2001, 76:911-20.
44. Pham TNQ, MacParland SA, Coffin CS. Mitogen-induced upregulation of hepatitis C virus expression in human lymphoid cells. J Gen Virol 2005, 86:657-66.
45. Frenkel N, Schirmer EC, Katsafanas G, June CH. T-cell activation is required for efficient replication of human herpesvirus 6. J Virol 1990, 64:4598-602.
46. Gowda SD, Stein BS, Mohagheghpour N. Evidence that T cell activation is required for HIV-1 entry in CD4+ lymphocytes. J Immunol 1989, 142:773-80.
47. Hyypia T, Korkiamaki P, Vainionpaa R. Replication of measles virus in human lymphocytes. J Exp Med 1985, 161:1261-71.
48. Castillo I, Bartolome J, Quiroga JA. Presence of HCV-RNA after ultracentrifugation of serum samples during the follow-up of chronic hepatitis C patients with a sustained virological response may predict reactivation of hepatitis C virus infection. Aliment Pharmacol Ther 2009, 30:477-86.
49. Marcellin P, Boyer N, Gervais A. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997, 127:875-81.
50. Formann E, Steindl-Munda P, Hofer H. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. Aliment Pharmacol Ther 2006, 23:507-11.
51. George SL, Bacon BR, Brunt EM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009, 49:729-38.
52. Reichard O, Glaumann H, Fryden A. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 1999, 30:783-7.
53. Camma C, Giunta M, Pinzello G. Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analyses of randomized controlled trials. Am J Gastroenterol 1999, 94:581-95.
54. Charlton M, Seaberg E, Wiesner R. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998, 28:823-30.
55. Nudo CG, Cortes RA, Weppler D. Effect of pretransplant hepatitis C virus RNA status on posttransplant outcome. Transplant Proc 2008, 40:1449-55.
56. Zhou S, Terrault NA, Ferrell L. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology 1996, 24:1041-6.
57. Lin A, Thadareddy A, Goldstein MJ, Lake-Bakaar G. Immune suppression leading to hepatitis C virus re-emergence after sustained virological response. J Med Virol 2008, 80:1720-2.
58. Thomopoulos K, Giannakoulas NC, Tsamandas AC. Recurrence of HCV infection in a sustained responder after chemotherapy for non-Hodgkin's lymphoma: successful retreatment. Am J Med Sci 2008, 336:73-6.
59. Lee WM, Polson JE, Carney DS. Reemergence of hepatitis C virus after 8.5 years in a patient with hypogammaglobulinemia: evidence for an occult viral reservoir. J Infect Dis 2005, 192:1088-92.
60. Mehta SH, Cox A, Hoover DR. Protection against persistence of hepatitis C. Lancet 2002, 359:1478-83.
61. Berasain C, Betes M, Panizo A. Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut 2000, 47:429-35.
62. Veldt BJ, Saracco G, Boyer N. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004, 53:1504-08.
63. Veldt BJ, Heathcote EJ, Wedemeyer H. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007, 147:677-84.
64. Makiyama A, Itoh Y, Kasahara A. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 2004, 101:1616-22.
65. Kobayashi S, Takeda T, Enomoto M. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter retrospective cohort study of 1124 patients. Liver Int 2007, 27:186-91.
66. Mashitani T, Yoshiji H, Yamazaki M. Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report. Case J 2009, 2. doi, 10.1186/1757-1626-2-18
67. Sanefuji K, Kayashima H, Iguchi T. Characterization of hepatocellular carcinoma developed after achieving sustained virological response to interferon therapy for hepatitis C. J Surg Oncol 2009, 99:32-7.
68. Tsuda N, Yuki N, Mochizuki K. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J Med Virol 2004, 74:406-13.
69. Cacoub P, Renou C, Rosenthal E. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine 2000, 79:47-56.
70. El Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002, 36:1439-45.
71. Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995, 123:615-20.
72. Pawlotsky JM, Ben Yahia M, Andre C. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994, 19:841-8.
73. Lunel F, Musset L, Cacoub P. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 1994, 106:1291-300.
74. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. Gastroenterology 2003, 125:1723-32.
75. Monti G, Pioltelli P, Saccardo F. Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med 2005, 165:101-5.
76. Bronowicki JP, Bineau C, Feugier P. Primary lymphoma of the liver: clinical-pathological features and relationship with HCV infection in French patients. Hepatology 2003, 37:781-7.
77. Kawamura Y, Ikeda K, Arase Y. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 2007, 120:1034-41.
78. McGuire BM, Julian BA, Bynon JS. Brief communication: glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med 2006, 144:735-41.
79. Fowell AJ, Sheron N, Rosenberg WM. Renal hepatitis C in the absence of detectable serum or hepatic virus. Liver Int 2008, 28:889-91.
80. Barril G, Castillo I, Arenas MD. Occult hepatitis C virus infection among hemodialysis patients. J Am Soc Nephrol 2008, 19:2288-92.
81. Casato M, Lilli D, Donato G. Occult hepatitis C virus infection in type II mixed cryoglobulinaemia. J Viral Hepat 2003, 10:455-9.
82. Pardo M, Castillo I, Rodrigues-Inigo E. Antiviral therapy in patients with occult HCV infection. Hepatology 2005, 42:658A.
83. MacParland SA, Pham TNQ, Guy CS, Michalak TI. Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitro. Hepatology 2009, 49:1431-41.
84. Feinstone SM, Alter HJ, Dienes HP. Non-A, non-B hepatitis in chimpanzees and marmosets. J Infect Dis 1981, 144:588-98.
85. Katayama K, Kumagai J, Komiya Y. Titration of hepatitis C virus in chimpanzees for determining the copy number required for transmission. Intervirology 2004, 47:57-64.
86. Castillo I, Bartolome J, Quiroga JA. Hepatitis C virus infection in the family setting of patients with occult hepatitis C. J Med Virol 2009, 81:1198-203.
87. Quiroga J, Casrtillo I, Llorente S. Identification of serologically silent occult hepatitis C virus infection be detecting immunoglobulin G antibody to a dominant HCV core protein epitope. J Hepatol 2009, 50:256-63.